A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice

American Journal of Pathology

Volumn 165, Issue 3, 2004, Pages 937-948

  Sadowski, Marcin ^a   Pankiewicz, Joanna ^a   Scholtzova, Henrieta ^a   Ripellino, James A ^a   Li, Yongsheng ^a   Schmidt, Stephen D ^b   Mathews, Paul M ^b   Fryer, John D ^c   Holtzman, David M ^c   Sigurdsson, Einar M ^a   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[12-28]; APOLIPOPROTEIN E; CHAPERONE; PROLINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VALINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FLUOROMETRY; HIPPOCAMPUS; IN VITRO STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 4344659648     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63355-X     Document Type: Article

References (88)

1. Selkoe DJ: The origins of Alzheimer disease: a is for amyloid. JAMA 2000, 283:1615-1617
2. Barrow CJ, Yasuda A, Kenny PT, Zagorski MG: Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease: analysis of circular dichroism spectra. J Mol Biol 1992, 225:1075-1093
3. Tomiyama T, Corder EH, Mori H: Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease. Cell Mol Life Sci 1999, 56:268-279
4. Wisniewski T, Castaño EM, Golabek AA, Vogel T, Frangione B: Accelaration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994, 145:1030-1035
5. Ma J, Yee A, Brewer Jr HB, Das S, Potter H: Amyloid-associated proteins α 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994, 372:92-94
6. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH: The Alzheimer's A β-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002, 99:11830-11835
7. Castaño EM, Prelli F, Wisniewski T, Golabek AA, Kumar RA, Soto C, Frangione B: Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. Biochem J 1995, 306:599-604
8. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:9649-9653
9. Rebeck GW, Reiter JS, Strickland DK, Hyman BT: Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993, 11:575-580
10. Yamaguchi H, Sugihara S, Ogawa A, Oshima N, Ihara Y: Alzheimer β amyloid deposition enhanced by ApoE ε 4 gene precedes neurofibrillary pathology in the frontal association cortex of non-demented senior subjects. J Neuropathol Exp Neurol 2001, 60:731-739
11. Golabek AA, Soto C, Vogel T, Wisniewski T: The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J Biol Chem 1996, 271:10602-10606
12. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 1997, 17:263-264
13. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977-1981
14. Wisniewski T, Golabek AA, Matsubara E, Ghiso J, Frangione B: Apolipoprotein E: binding to soluble Alzheimer's β-amyloid. Biochem Biophys Res Commun 1993, 192:359-365
15. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C: Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 1995, 15: 219-228
16. Golabek AA, Marques M, Lalowski M, Wisniewski T: Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 1995, 191:79-82
17. Shuvaev VV, Siest G: Interaction between human amphipathic apolipoproteins and amyloid β-peptide: surface plasmon resonance studies. FEBS Lett 1996, 383:9-12
18. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD: Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:8098-8102
19. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R: A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002, 99:16742-16747
20. Ma J, Brewer BH, Potter H, Brewer Jr HB: Alzheimer Aβ neurotoxicity: promotion by antichymotrypsin, apoE4; inhibition by Aβ-related peptides. Neurobiol Aging 1996, 17:773-780
21. Gorevic PD, Castaño EM, Sarma R, Frangione B: Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic x-ray diffraction pattern. Biochem Biophys Res Commun 1987, 147:854-862
22. Wengenack TM, Curran GL, Poduslo JF: Targeting Alzheimer amyloid plaques in vivo. Nat Biotech 2000, 18:868-872
23. Sigurdsson EM, Permanne B, Soto C, Wisniewski T, Frangione B: In vivo reversal of amyloid β lesions in rat brain. J Neuropathol Exp Neurol 2000, 59:11-17
24. Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T: Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 2001, 159:439-447
25. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J: Apolipoprotein J and Alzheimer's amyloid β solubility. Biochem J 1996,316:671-679
26. Stine WB, Dahlgren KN, Krafft GA, LaDu MJ: In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J Biol Chem 2003, 278:11612-11622
27. Pagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA, LaDu MJ: Unique lipoproteins secreted by primary astrocytes from wild-type, apoE (-/-), and human apoE transgenic mice. J Biol Chem 1999, 274: 30001-30007
28. DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, Sullivan PM, Fagan AM, Han XL, Holtzman DM: Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int 2001, 39:415-425
29. Sun YL, Wu S, Bu GJ, Onifade MK, Patel SN, LaDu MJ, Fagan AM, Holtzman DM: Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998, 18:3261-3272
30. Soto C, Golabek AA, Wisniewski T, Castaño EM: Alzheimer's soluble β-amyloid is conformationally modified by apolipoproteins in vitro. Neuroreport 1996, 7:721-725
31. Greenfield N, Fasman GD: Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry 1969, 8:4108-4115
32. Perczel A, Park K, Fasman GD: Analysis of circular dichroism spectrum of proteins using the convex constraint algorithim. Anal Biochem 1992, 203:83-93
33. Manavalan P, Johnson C: Variable selection method improves the prediction of protein secondary structure from circular dichroism. Anal Biochem 1987, 167:76-85
34. Toumadje A, Alcorn SW, Johnson C: Extending CD spectra of proteins to 168nm improves the analysis for secondary structures. Anal Biochem 1992, 200:321-331
35. Sreerma N, Woody RW: A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal Biochem 1993, 209:32-44
36. Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW: Induced expression of neuronal membrane attack complex and cell death by Alzheimer's β-amyloid peptide. Brain Res 1998, 796:187-197
37. Wei WL, Wang XT, Kusiak JW: Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 2002, 277:17649-17656
38. Matsubara E, Frangione B, Ghiso J: Characterization of apolipoprotein J-Alzheimer's A β interaction. J Biol Chem 1995, 270:7563-7567
39. Bolton AE, Hunter WM: Labeling of proteins to high-specific radioactivities by conjugation to A 1-125-containing acylating agent: application to radioimmunoassay. Biochem J 1973, 133:529-538
40. Vaidyanathan G, Affleck DJ, Zalutsky MR: Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. Bioconjug Chem 1993, 4:78-84
41. Haugland RP, Bhalgat MK: Preparation of avidin conjugates. The Protein Protocols Handbook. Edited by Walker JM. Totowa NJ, Humana Press, 2002, pp 365-374
42. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, Frangione B, Ghiso J: Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid β. Biochem Biophys Res Commun 1994, 205:1431-1437
43. Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B: Blood-brain barrier transport of circulating Alzheimer's amyloid β. Biochem Biophys Res Commun 1993, 197:1034-1040
44. Grutzendler J, Kasthuri N, Gan WB: Long-term dendritic spine stability in the adult cortex. Nature 2002, 420:812-816
45. Deane R, Yan SD, Submamaryan RK, Larue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B: RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9:907-913
46. Lalowski M, Golabek AA, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B, Wisniewski T: The "non-amyloidogenic" p3 fragment (Aβ17-42) is a major constituent of Down syndrome cerebellar preamyloid. J Biol Chem 1996, 271:33623-33631
47. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F, Soto C: Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide. EMBO J 2002, 16:U165-U188
48. Shargel L, Yu CEA: Applied Biopharmaceutics and Pharmakokinetics. New York, McGraw-Hill, 1999
49. Morton DB, Griffiths PH: Guidelines on the recognition of pain, distress, and discomfort in experimental animals and an hypothesis for assessment. Vet Rec 1985, 116:431-436
50. Stokes A: Humane endpoints in animal experiments for laboratory animals used in toxicity testing. Proceedings of the 3rd World Congress on Alternatives and Animal Use in Life Sciences. Bologna, Italy, 1999
51. Hsiao KK, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science 1996, 274:99-102
52. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-Tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S: Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713
53. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D: Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 1999, 29:177-185
54. Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF: Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 2000, 101:939-944
55. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, Yu X, Uljon S, Wang R, Mann D, Dickson D, Duff K: Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 1999, 6:231-244
56. Sadowski M, Wisniewski HM, Jakubowska-Sadowska K, Tarnawski M, Lazarewicz JW, Mossakowski MJ: Pattern of neuronal loss in the rat hippocampus following experimental cardiac arrest-induced ischemia. J Neurol Sci 1999, 168:13-20
57. Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie J, Wisniewski HM: Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 1988, 2:121-130
58. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J: Diffuse, lake-like amyloid-β deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 1998, 57:674-683
59. West MJ, Gundersen HJG: Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990, 296:1-22
60. West MJ, Slomianka L, Gundersen HJG: Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991, 231:482-497
61. Gundersen HJG, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ: Some new, simple and efficient stereological methods and their use in pathological research and diagnosis: review article. APMIS 1988, 96:379-394
62. Sadowski M, Wen PH, Elder GA, Robakis NK, Wisniewski T: Effect of the presenilin 1 P117LFAD linked mutation on hippocampal morphology transgenic mice. J Neuropathol Exp Neurol 2001, 60:543
63. Wadghiri YZ, Sigurdsson EM, Sadowski M, Li Y, Pappolla MA, Duff K, Turnbull D, Wisniewski T: Detection of Alzheimer's amyloid lesions in transgenic mice by magnetic resonance imaging. Magn Reson Med 2003, 50:293-302
64. Jimenez-Huete A, Alfonso P, Soto C, Albar JP, Rabano A, Ghiso J, Frangione B: Antibodies directed to the carboxyl terminus of amyloid β-peptide recognize sequence epitopes and distinct immunoreactive ' deposits in Alzheimer's disease brain. Alzheimers Rep 1998, 1:41-47
65. Wisniewski T, Frangione B: Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992, 135:235-238
66. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic BV, Smith JD, LaDu MJ, Rostagno A, Frangione B, Ghiso J: Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. Biochem J 2000, 348:359-365
67. Poduslo JF, Curran GL, Sanyal B, Selkoe DJ: Receptor-mediated transport of human amyloid β-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis 1999, 6:190-199
68. Mirra SS, Gearing M, Nash F: Neuropathologic assessment of Alzheimer's disease. Neurology 1997, 49:S14-S16
69. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM: Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999, 96:15233-15238
70. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM: Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999, 103:R15-R21
71. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM: Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000, 97:2892-2897
72. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME, Mantyh PW: Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992, 89:5462-5466
73. Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, Hyman BT: Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci 2001, 21:858-864
74. Wisniewski T, Lalowski M, Golabek AA, Vogel T, Frangione B: Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 1995, 345:956-958
75. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106: 1489-1499
76. Zlokovic BV: Cerebrovascular transport of Alzheimer's amyloid β and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci 1996, 59:1483-1497
77. Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, Wisniewski T: Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimer Dis 2001, 3:23-30
78. DeMattos RB, O'Dell M, Taylor JW, Parsadanian M, Bales KR, Paul SM, Holtzman DM: Early and marked increase in a-β deposition in PDAPP mice in the absence of both apoe and clusterin: evidence for a cooperative role in a-β clearance in vivo. 2003 Abstract Viewer/ Itinerary Planner. Washington, DC, Society for Neuroscience, 2003, Program No. 666.14
79. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177
80. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2001, 408:982-985
81. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe D: Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000, 48:567-579
82. Greenberg SM, Bacskai BJ, Hyman BT: Alzheimer disease's double-edged vaccine. Nat Med 2003, 9:389-390
83. Doerfler P, Shearman MS, Perlmutter RM: Presenilin-dependent γ-secretase activity modulates thymocyte development. Proc Natl Acad Sci USA 2001, 98:9312-9317
84. Figueroa DJ, Morris JA, Ma L, Kandpal G, Chen E, Li YM, Austin CP: Presenilin-dependent γ-secretase activity modulates neurite outgrowth. Neurobiol Dis 2002, 9:49-60
85. Hadland BK, Manley NR, Su DM, Longmore GD, Moore CL, Wolfe MS, Schroeter EH, Kopan R: γ-secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA 2001, 98:7487-7491
86. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C: A γ-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002, 3:688-694
87. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mice. Nature 1999, 400:173-177
88. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant KM: The γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003, 305:864-871